Drugs /

pv-10

Back to Drugs List

Overview

NCI Definition [1]:
An injectable ten percent solution of rose bengal disodium, an iodinated fluorescein derivative, with potential antineoplastic and radiosensitizing activities. When injected into tumor tissue, PV-10 specifically targets and concentrates in tumor cells, producing cytotoxic singlet oxygen when exposed to ionizing radiation. In addition, PV-10 may stimulate an anti-tumor immune response.

Clinical Trials

View Clinical Trials for pv-10

Pv-10 has been investigated in 3 clinical trials, of which 3 are open and 0 are closed. Of the trials investigating pv-10, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open).

SSTR1 Expression, SSTR2 Expression, and SSTR3 Expression are the most frequent biomarker inclusion criteria for pv-10 clinical trials.

Malignant solid tumor, melanoma, and neuroendocrine carcinoma are the most common diseases being investigated in pv-10 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Pv-10
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating pv-10 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
4,5,6,7-tetrachloro-2',4',5',7'-tetraiodofluorescein disodium salt, provecta, injectable rose bengal 10%, rose bengal disodium 10%, rose bengal disodium 10%
NCIT ID [1]:
C53412

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.